Ulrich Dauer
Directeur/Membre du Conseil chez Atriva Therapeutics GmbH
Fortune : 26 719 $ au 30/04/2024
Postes actifs de Ulrich Dauer
Sociétés | Poste | Début | Fin |
---|---|---|---|
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Ulrich Dauer
Anciens postes connus de Ulrich Dauer
Sociétés | Poste | Début | Fin |
---|---|---|---|
VIVORYON THERAPEUTICS N.V. | Directeur/Membre du Conseil | - | 14/08/2023 |
Directeur Général | 01/05/2018 | 14/08/2023 | |
Directeur Financier/CFO | 01/05/2018 | 01/04/2021 | |
4SC AG | Directeur Général | 01/01/1997 | 31/03/2013 |
Fondateur | 01/01/1997 | 31/03/2013 | |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Directeur Général | 24/05/2017 | - |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Directeur Général | - | - |
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Corporate Officer/Principal | 01/11/2013 | - |
Formation de Ulrich Dauer
Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Statistiques
Internationale
Allemagne | 8 |
Opérationnelle
Chief Executive Officer | 4 |
Director/Board Member | 2 |
Founder | 1 |
Sectorielle
Health Technology | 7 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
4SC AG | Health Technology |
VIVORYON THERAPEUTICS N.V. | Health Technology |
Entreprise privées | 4 |
---|---|
Vectura GmbH
Vectura GmbH Medical SpecialtiesHealth Technology Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany. | Health Technology |
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
Ventaleon GmbH
Ventaleon GmbH Pharmaceuticals: OtherHealth Technology Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany. | Health Technology |
Atriva Therapeutics GmbH
Atriva Therapeutics GmbH BiotechnologyHealth Technology Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany. | Health Technology |
- Bourse
- Insiders
- Ulrich Dauer
- Expérience